Cybin completes enrollment in Phase 2 study of CYB004 for generalized anxiety disorder

Cybin Inc. (CYBN) — Cybin finished enrolling its Phase 2 trial of CYB004, a proprietary deuterated DMT candidate, in patients with generalized anxiety disorder.

The study enrolled 36 participants and assesses safety and efficacy at 12 weeks after the first dose, with topline data reaffirmed for the first quarter of 2026. The milestone keeps Cybin's second clinical program on schedule alongside its lead CYB003 depression asset.

Source: ir.cybin.com

For the rest of that week's sector news, read our week in review.